11 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | TAO, BIN | 1625 | Non-Final OA | Jan 05, 2024 |
| 18562428 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN | VALENROD, YEVGENY | 1628 | Non-Final OA | Nov 20, 2023 |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Nov 15, 2023 |
| 18288275 | Pharmaceutical Composition for Preventing or Treating Fibrosis | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | Non-Final OA | Oct 25, 2023 |
| 18288296 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS | OH, TAYLOR V | 1625 | Non-Final OA | Oct 25, 2023 |
| 18022982 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | MCMILLIAN, KARA RENITA | 1623 | Final Rejection | Feb 23, 2023 |
| 17799774 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | JARRELL, NOBLE E | 1699 | Non-Final OA | Aug 15, 2022 |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 1693 | Final Rejection | May 06, 2022 |
| 17772855 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | Apr 28, 2022 |
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 1623 | Non-Final OA | Nov 10, 2021 |
| 17434389 | ALBUMIN-BOUND COMPOSITION INCLUDING LRRD2 OF SLIT3 PROTEIN FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASES | BEANE, RANDALL L | 1654 | Final Rejection | Aug 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial